Enhancing effect of pyrrolidone derivatives on transdermal penetration of 5-fluorouracil, triamcinolone acetonide, indomethacin, and flurbiprofen
Sasaki, H; Kojima, M; Mori, Y; Nakamura, J; Shibasaki, J
| HERO ID | 1620004 |
|---|---|
| In Press | No |
| Year | 1991 |
| Title | Enhancing effect of pyrrolidone derivatives on transdermal penetration of 5-fluorouracil, triamcinolone acetonide, indomethacin, and flurbiprofen |
| Authors | Sasaki, H; Kojima, M; Mori, Y; Nakamura, J; Shibasaki, J |
| Journal | Journal of Pharmaceutical Sciences |
| Volume | Pharm |
| Issue | REF 25 |
| Page Numbers | 533-538 |
| Abstract | IPA COPYRIGHT: ASHP The enhancing effects of 3 pyrrolidones on the transdermal penetration of fluorouracil (5-fluorouracil), triamcinolone acetonide, indomethacin and flurbiprofen were studied in vitro using full-thickness rat skin. The pyrrolidones enhanced the penetration of the penetrants, especially the lipophilic derivatives, which showed great enhancing effects on the penetration of fluorouracil and indomethacin. The more lipophilic pyrrolidones showed greater enhancing effects on the solubility and penetration of hydrophilic penetrants than those of lipophilic penetrants. The pyrrolidones also enhanced the solubility of the penetrants in isopropyl myristate. All enhancers accumulated to a great extent in the skin and enhanced the skin retention of the drugs. It was concluded that the pyrrolidone derivatives enhance the flux of penetrants in the skin by increasing their solubility. |
| Pmid | 1941542 |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |
| Language Text | English |
| Keyword | <?xml version="1.0" encoding="UTF-8"?><kw>Fluorouracil</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Triamcinolone acetonide</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Indomethacin</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Flurbiprofen</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Isopropyl myristate</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>solvents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>drug solubility</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Pyrrolidones</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>effects</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous drug absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Antineoplastic agents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>percutaneous absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>fluorouracil(Antineoplastic agents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Steroids</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>triamcinolone acetonide(Steroids</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Anti-inflammatory agents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>indomethacin(Anti-inflammatory agents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>flurbiprofen(Anti-inflammatory agents</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>drugs</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Solubility</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>effects</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Lipophilicity</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>Absorption enhancers</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>drug absorption</kw>; <?xml version="1.0" encoding="UTF-8"?><kw>5-Fluorouracil</kw> |